Skip to main content
. 2022 Oct 28;13:1019772. doi: 10.3389/fimmu.2022.1019772

Table 5.

Adverse events related to anti-PD-1 treatment.

Variable Experimental group (n=15)
Treatment-related adverse events. 9 (60%)
Grade 1–2 adverse events 8 (53.3%)
Adverse events of ≥grade 3 1 (6.7%)
Serious adverse events 1 (6.7%)
Serious adverse events leading to drug discontinuation 1 (6.7%)
Serious adverse events leading to death 0